Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q4 FY2024 Earnings Presentation
18 slides from Ngl Fine-chem's earnings presentation, May 2024
Slide 1: NGL Fine-Chem Limited Investor Presentation Q4 & FY24
NGL Fine-Chem Limited INVESTOR PRESENTATION Q4 & FY24
Slide 2: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be d
Slide 3: Inside This Presentation
Inside This Presentation Pg. No. Pg. No. 04 11 Q4 & FY24 Over view, Highlights Key Strengths and Strategy Pg. No. 16 Historical Financial Performance
Slide 4: Q4 & FY24 Highlights
01 Q4 & FY24 Highlights 05 M A N A G E M E N T C O M M E N TA R Y 06 Q U A R T E R LY O P E R AT I O N A L M E T R I C S 07 F U L L Y E A R O P E R AT I O N A L M E T R I C S 08 S U M M A R Y O F F I N A N C I A L S TAT E M E N T S
Slide 5: Management Commentary
MANAGEMENT COMMENTARY Dear Shareholders, n a vi g a t e t h e vo l a t i l e m a rk et c o n d i t i o n s ef f ec t i vel y a n d su st a i n o u r g ro wt h m o m en t u m . R ef l ec t i n g o n t h e f u l l y ea r, I a m p l ea sed t o rep o rt t h a t N G L F i n e- C h em L i m i t ed h a s d
Slide 6: Operational Metrics
Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS Q4FY23 Q3FY24 Q4FY24 PARTICULARS Q4FY23 Q3FY24 Q4FY24 ANIMAL API 81% 94% 90% TOP 3 PRODUCTS 41% 36% 34% HUMAN API 3% 2% 3% TOP 5 PRODUCTS 58% 51% 49% INTERMEDIATES 11% 2% 3% TOP 10 PRODUCTS 78% 72% 72% FORMULATIONS 4% 2% 4%
Slide 7: Full Year Operational Metrics
Full Year Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS FY22 FY23 FY24 PARTICULARS FY22 FY23 FY24 ANIMAL API 81% 83% 89% TOP 3 PRODUCTS 37% 34% 32% HUMAN API 7% 5% 3% TOP 5 PRODUCTS 52% 47% 46% INTERMEDIATES 9% 7% 3% TOP 10 PRODUCTS 76% 72% 61% FORMULATIONS 3% 5% 5% GEO
Slide 8: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement ₹ IN CRORES PARTICUL ARS Q4FY23 Q3FY24 Q4FY24 Q-o-Q Y-o-Y FY23 FY24 Y-o-Y REVENUE FROM OPERATIONS 73.89 87.95 99.76 13.43% 35.01% 278.08 338.68 21.79% OTHER INCOME 2.10 3.68 3.68 0.00% 75.24% 5.53 14.13 155.52% TOTAL INCOME 75.99 91.63 103.44 12.89% 36.12% 283.61
Slide 9: Summary of Balance Sheet
Summary of Balance Sheet ₹ IN CRORES PARTICUL ARS FY23 FY24 SHAREHOLDERS FUND 222.55 262.63 NON CURRENT LIABILITIES 6.23 6.32 LONG TERM BORROWINGS 2.07 0.75 CURRENT LIABILITIES 58.30 86.59 SHORT TERM BORROWINGS 28.41 31.70 TOTAL EQUITY AND LIABILITIES 287.08 355.54 NON CURRENT ASSETS 124.43 142.87 N
Slide 10: Summary of Cash Flow Statement
Summary of Cash Flow Statement ₹ IN CRORES PARTICUL ARS FY23 FY24 CASH FLOW FROM OPERATING ACTIVITIES 35.29 20.47 CASH FLOW FROM INVESTING ACTIVITIES (27.02) (26.82) CASH FLOW FROM FINANCING ACTIVITIES (1.08) (1.08) NET CASH FLOW 7.18 (7.43) CASH AT THE BEGINNING OF YEAR 0.64 7.83 CASH AT THE END OF
Slide 11: Overview, Strengths and Strategy
02 Overview, Strengths and Strategy 12 L E A D I N G A N I M A L H E A LT H C O M PA N Y 13 LEADERSHIP IN VETERINARY API SEGMENT 14 S TAT E - O F - T H E - A R T M A N U FA C T U R I N G C A PA B I L I T I E S 15 S T R AT E G Y F O R N E X T L E G O F G R O W T H
Slide 12: Leading Animal Health Company
Leading Animal Health Company COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 26 APIs (24 Veterinary • Leadership in top • 3 state of the art • 45+ countries across • ~400 customers APIs, 2 Huma
Slide 13: Leadership in Veterinary API Segment
Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT Strong controls of processes with 95% in-house manufacturing and API SEGMENT (₹ IN CRORES) 22% CAGR CONCENTRATION (OF SALES FY24) backward integrated facilities leading to cost competitiveness FY24 300 CUSTOMER PRODUCT F
Slide 14: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabilities HIGHLIGHTS 3 manufacturing facilities located at Tarapur & Navi 10,000 m 2 102 m 3 194 m 3 AREA OF GLASS-LINED STAINLESS STEEL Mumbai, Maharashtra, MANUFACTURING REACTORS REACTORS designed to meet the FACILITIES requirements of regulatory agencies and are
Slide 15: Strategy for next leg of growth
Strategy for next leg of growth BROWNFIELD EXPANSION • Completed expansion in ONGOING INITIATIVES subsidiary Macrotech TO INCREASE • Additional capacities of a CAPACITIES TO MEET intermediates GROWING DEMAND • Commercial production started GREENFIELD EXPANSION AT TARAPUR • 50% capacity expansion wit
Slide 16: Historical Financial Performance
03 Historical Financial Performance 17 ROBUST FINANCIAL PERFORMANCE
Slide 17: Robust Financial Performance
Robust Financial Performance REVENUE EBITDA PAT (₹ IN CRORES) (₹ IN CRORES) (₹ IN CRORES) FY24 339 FY24 53 FY24 41 FY23 278 FY23 34 FY23 21 FY22 318 FY22 68 FY22 50 FY21 258 FY21 80 FY21 57 FY20 152 FY20 19 FY20 8 0 50 100 150 200 250 300 350 400 0 10 20 30 40 50 60 70 80 90 0 10 20 30 40 50 60 GROS
Slide 18: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Thank You Pallavi Pednekar Abhishek Mehra NGL FINE-CHEM TIL ADVISORS PRIVATE LIMITED LIMITED cs@nglfinechem.com abhishek@theinvestmentlab.in +91 22 40842222 +91 95588 14500 Corporate Office 301, E-square, Subhash Road, Vile Parle (East), Mumbai - 400057, M